Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373520 | 0.86 | KDM4E (0.41) | CMA1PTGS2DYRK1AADORA2AADORA1 | |
| SCHEMBL21373515 | 0.86 | MAPT (0.44) | CMA1DYRK1AMEN1NPC1RAB9A | |
| SCHEMBL21373535 | 0.86 | PIM1 (0.40) | CMA1DYRK1AMEN1NPC1RAB9A | |
| SCHEMBL21373608 | 0.86 | GRM1 (0.43) | CMA1PTGS2DYRK1AMEN1NPC1 | |
| SCHEMBL21373517 | 0.83 | MAP2K4 (0.40) | CMA1PTGS2DYRK1AMEN1KMT2A | |
| SCHEMBL21373507 | 0.83 | CMA1 (0.38) | CMA1DYRK1ANPC1KMT2AHCAR1 | |
| SCHEMBL21373483 | 0.77 | CMA1 (0.46) | CMA1DYRK1AMEN1KMT2AHCAR1 | |
| SCHEMBL21381493 | 0.75 | SMN1; SMN2 (0.47) | CMA1KMT2ASMN1; SMN2PKMKDM4E | |
| SCHEMBL21373529 | 0.74 | BRD9 (0.45) | CMA1PTGS2EDNRBEDNRASMN1; SMN2 | |
| SCHEMBL21373636 | 0.73 | CMA1 (0.43) | CMA1DYRK1AKMT2APKMHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | claimed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | claimed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-116462666-A | Cytoprotective compounds and uses thereof | 瑞士苏黎世联邦理工学院 | 2023-07-21 | — | — | CN | disclosed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | SRPK2, SRSF2, SRPK1 | CMA1 3847/4885PTGS2 512/4885DYRK1A 2912/4885 |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | CMA1 1512/4885PTGS2 3201/4885DYRK1A 4488/4885 |
| US-11628159-B2 | Cell-protective compounds and their use | SRPK2, SRSF2, SRPK1 | CMA1 3847/4885PTGS2 512/4885DYRK1A 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.